The success of Sildenafil initially sparked a boom for pharma, but recent shifts present a uncertain picture for those considering a stake. Lower-cost versions are eroding earnings, and continued legal battles add further difficulty to the situation. While certain companies could still gain from adjacent products, the broader trajectory suggests… Read More